KRAS and non-small cell lung carcinoma: In this regard, dipeptidyl peptidase 4 (DPP4; also known as CD26), an enzyme that regulates immune responses and maintains cellular homeostasis, is a potential therapeutic target in KRAS-mutant NSCLC.